Order Article Reprints

Mejía-Hernández JO, Raghu D, Caramia F, Clemons N, Fujihara K, Riseborough T, Teunisse A, Jochemsen AG, Abrahmsén L, Blandino G, et al. Targeting MDM4 as a Novel Therapeutic Approach in Prostate Cancer Independent of p53 Status. Cancers. 2022; 14(16):3947. https://doi.org/10.3390/cancers14163947

Mejía-Hernández, Javier Octavio, Dinesh Raghu, Franco Caramia, Nicholas Clemons, Kenji Fujihara, Thomas Riseborough, Amina Teunisse, Aart G. Jochemsen, Lars Abrahmsén, Giovanni Blandino, and et al. 2022. "Targeting MDM4 as a Novel Therapeutic Approach in Prostate Cancer Independent of p53 Status" Cancers 14, no. 16: 3947. https://doi.org/10.3390/cancers14163947

Mejía-Hernández, J. O., Raghu, D., Caramia, F., Clemons, N., Fujihara, K., Riseborough, T., Teunisse, A., Jochemsen, A. G., Abrahmsén, L., Blandino, G., Russo, A., Gamell, C., Fox, S. B., Mitchell, C., Takano, E. A., Byrne, D., Miranda, P. J., Saleh, R., Thorne, H., ... Haupt, S. (2022). Targeting MDM4 as a Novel Therapeutic Approach in Prostate Cancer Independent of p53 Status. Cancers, 14(16), 3947. https://doi.org/10.3390/cancers14163947